{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:35:34Z","timestamp":1790861734963,"version":"4.1.0"},"reference-count":139,"publisher":"European Respiratory Society (ERS)","issue":"6","funder":[{"name":"Consorzio Futuro in Ricerca of Ferrara, Italy","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,8,23]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>\n                    The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can result in clear clinical benefits in some patients (\u201cfriend\u201d) but can be ineffective or even associated with undesired side effects,\n                    <jats:italic>e.g.<\/jats:italic>\n                    pneumonia, in others (\u201cfoe\u201d). After critically reviewing the evidence for and against ICS treatment in patients with COPD, we propose that: 1) ICS should not be used as a single, stand-alone therapy in COPD; 2) patients most likely to benefit from the addition of ICS to long-acting bronchodilators include those with history of multiple or severe exacerbations despite appropriate maintenance bronchodilator use, particularly if blood eosinophils are &gt;300\u2005cells\u00b7\u00b5L\n                    <jats:sup>\u22121<\/jats:sup>\n                    , and those with a history of and\/or concomitant asthma; and 3) the risk of pneumonia in COPD patients using ICS is higher in those with older age, lower body mass index (BMI), greater overall fragility, receiving higher ICS doses and those with blood eosinophils &lt;100\u2005cells\u00b7\u00b5L\n                    <jats:sup>\u22121<\/jats:sup>\n                    . All these factors must be carefully considered and balanced in any individual COPD patient before adding ICS to her\/his maintenance bronchodilator treatment. Further research is needed to clarify some of these issues and firmly establish these recommendations.\n                  <\/jats:p>","DOI":"10.1183\/13993003.01219-2018","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T08:05:39Z","timestamp":1536221139000},"page":"1801219","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":212,"title":["Inhaled corticosteroids in COPD: friend or foe?"],"prefix":"10.1183","volume":"52","author":[{"given":"Alvar","family":"Agusti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-1689","authenticated-orcid":false,"given":"Leonardo M.","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1633-6356","authenticated-orcid":false,"given":"Frits M.E.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus F.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-4500","authenticated-orcid":false,"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"2024102100362530000_52.6.1801219.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906243402503"},{"key":"2024102100362530000_52.6.1801219.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10019-3"},{"key":"2024102100362530000_52.6.1801219.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00027003"},{"key":"2024102100362530000_52.6.1801219.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00031402"},{"key":"2024102100362530000_52.6.1801219.5","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/COPD.S136527","article-title":"Fluticasone propionate\/formoterol for COPD management: a randomized controlled trial","volume":"12","author":"Papi","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102100362530000_52.6.1801219.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.008"},{"key":"2024102100362530000_52.6.1801219.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-244OC"},{"key":"2024102100362530000_52.6.1801219.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.04.019"},{"key":"2024102100362530000_52.6.1801219.9","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969050-00004"},{"key":"2024102100362530000_52.6.1801219.10","doi-asserted-by":"publisher","DOI":"10.1080\/15412550903140881"},{"key":"2024102100362530000_52.6.1801219.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.020"},{"key":"2024102100362530000_52.6.1801219.12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir Med"},{"key":"2024102100362530000_52.6.1801219.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12459-2"},{"key":"2024102100362530000_52.6.1801219.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"2024102100362530000_52.6.1801219.16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"2024102100362530000_52.6.1801219.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2024102100362530000_52.6.1801219.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30206-X"},{"key":"2024102100362530000_52.6.1801219.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01531-2017"},{"key":"2024102100362530000_52.6.1801219.20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/fampra\/cmx124","article-title":"Number of patients needed to prescribe statins in primary cardiovascular prevention: mirage and reality","volume":"35","author":"Rossignol","year":"2018","journal-title":"Fam Pract"},{"key":"2024102100362530000_52.6.1801219.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002410"},{"key":"2024102100362530000_52.6.1801219.22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMe1716802","article-title":"Making sense of triple inhaled therapy for COPD","volume":"378","author":"Suissa","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102100362530000_52.6.1801219.23","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0140-6736(17)30567-6","article-title":"Triple therapy for symptomatic patients with COPD","volume":"389","author":"Fabbri","year":"2017","journal-title":"Lancet"},{"key":"2024102100362530000_52.6.1801219.24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(18)30252-6","article-title":"Filling the gaps in COPD: the TRIBUTE study","volume":"391","author":"Agusti","year":"2018","journal-title":"Lancet"},{"key":"2024102100362530000_52.6.1801219.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068307"},{"key":"2024102100362530000_52.6.1801219.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-973OC"},{"key":"2024102100362530000_52.6.1801219.27","first-page":"A1015","article-title":"Reduction in all-cause mortality with single inhaler triple therapy (FF\/UMEC\/VI) versus dual therapy (FF\/VI and UMEC\/VI) in symptomatic patients with COPD: prespecified analysis of the Phase III IMPACT Trial","volume":"197","author":"Lipson","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01230-2018"},{"key":"2024102100362530000_52.6.1801219.29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/1389450111314020006","article-title":"Inhaled corticosteroids in COPD: pros and cons","volume":"14","author":"Zervas","year":"2013","journal-title":"Curr Drug Targets"},{"key":"2024102100362530000_52.6.1801219.30","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.4.2009033"},{"key":"2024102100362530000_52.6.1801219.31","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00301302"},{"key":"2024102100362530000_52.6.1801219.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200502-210OC"},{"key":"2024102100362530000_52.6.1801219.33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/15412555.2015.1044861","article-title":"The effect on total mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: a real practice analysis in Italy","volume":"13","author":"Di Martino","year":"2016","journal-title":"COPD"},{"key":"2024102100362530000_52.6.1801219.34","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0655"},{"key":"2024102100362530000_52.6.1801219.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02569-2017"},{"key":"2024102100362530000_52.6.1801219.36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.chest.2018.04.006","article-title":"Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned","volume":"154","author":"Suissa","year":"2018","journal-title":"Chest"},{"key":"2024102100362530000_52.6.1801219.37","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn135"},{"key":"2024102100362530000_52.6.1801219.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.11432"},{"key":"2024102100362530000_52.6.1801219.39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01567-2017"},{"key":"2024102100362530000_52.6.1801219.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01612-2017"},{"key":"2024102100362530000_52.6.1801219.41","doi-asserted-by":"crossref","unstructured":"Horita N , Goto A , Shibata Y , et\u00a0al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2017: CD012066.","DOI":"10.1002\/14651858.CD012066"},{"key":"2024102100362530000_52.6.1801219.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201310-1863PP"},{"key":"2024102100362530000_52.6.1801219.43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.002"},{"key":"2024102100362530000_52.6.1801219.45","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-178"},{"key":"2024102100362530000_52.6.1801219.46","first-page":"124","article-title":"Responder analyses for treatment effects in COPD using the St George's Respiratory Questionnaire","volume":"4","author":"Jones","year":"2017","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2024102100362530000_52.6.1801219.47","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201412-2269OC"},{"key":"2024102100362530000_52.6.1801219.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105482"},{"key":"2024102100362530000_52.6.1801219.49","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0831OC"},{"key":"2024102100362530000_52.6.1801219.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411532"},{"key":"2024102100362530000_52.6.1801219.51","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200712-1869OC"},{"key":"2024102100362530000_52.6.1801219.52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1164\/rccm.201610-2086OC","article-title":"SUMMIT (Study to Understand Mortality and Morbidity) Investigators. Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk","volume":"197","author":"Calverley","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.53","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.11.937"},{"key":"2024102100362530000_52.6.1801219.54","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1164\/rccm.201710-2052LE","article-title":"Long-acting \u03b2-agonist\/inhaled corticosteroid in patients with chronic obstructive pulmonary disease with cardiovascular disease or risk: a factorial analysis of the SUMMIT clinical trial","volume":"197","author":"Celli","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.55","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01370-2015"},{"key":"2024102100362530000_52.6.1801219.56","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202878"},{"key":"2024102100362530000_52.6.1801219.57","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-12-200306170-00008"},{"key":"2024102100362530000_52.6.1801219.58","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-1696"},{"key":"2024102100362530000_52.6.1801219.59","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201591"},{"key":"2024102100362530000_52.6.1801219.60","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00125404"},{"key":"2024102100362530000_52.6.1801219.61","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200701-024FM"},{"key":"2024102100362530000_52.6.1801219.62","first-page":"43","article-title":"Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial","volume":"7","author":"Tashkin","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102100362530000_52.6.1801219.63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2016.09.015","article-title":"Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device","volume":"120","author":"Dekhuijzen","year":"2016","journal-title":"Respir Med"},{"key":"2024102100362530000_52.6.1801219.64","first-page":"971","article-title":"Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis","volume":"6","author":"Ni","year":"2014","journal-title":"J Thorac Dis"},{"key":"2024102100362530000_52.6.1801219.65","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2137"},{"key":"2024102100362530000_52.6.1801219.66","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00095807"},{"key":"2024102100362530000_52.6.1801219.67","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-206780"},{"key":"2024102100362530000_52.6.1801219.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516385"},{"key":"2024102100362530000_52.6.1801219.69","doi-asserted-by":"crossref","unstructured":"Nannini LJ , Poole P , Milan SJ , et\u00a0al. Combined corticosteroid and long-acting beta 2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013: CD003794.","DOI":"10.1002\/14651858.CD003794.pub4"},{"key":"2024102100362530000_52.6.1801219.70","doi-asserted-by":"crossref","unstructured":"Nannini LJ , Lasserson TJ , Poole P . Combined corticosteroid and long-acting beta 2-agonist in one inhaler versus long-acting beta 2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012: CD006829.","DOI":"10.1002\/14651858.CD006829.pub2"},{"key":"2024102100362530000_52.6.1801219.71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2016.11.003","article-title":"A systematic review with meta-analysis of fluticasone furoate\/vilanterol combination for the treatment of stable COPD","volume":"42","author":"Rodrigo","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102100362530000_52.6.1801219.72","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202872"},{"key":"2024102100362530000_52.6.1801219.73","doi-asserted-by":"crossref","unstructured":"Kew KM , Seniukovich A . Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014: CD010115.","DOI":"10.1002\/14651858.CD010115.pub2"},{"key":"2024102100362530000_52.6.1801219.74","unstructured":"European Medicines Agency. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD) (EMA\/330021\/2016) . London, UK, 2016."},{"key":"2024102100362530000_52.6.1801219.75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30188-5"},{"key":"2024102100362530000_52.6.1801219.76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31354-X"},{"key":"2024102100362530000_52.6.1801219.77","first-page":"A3030","article-title":"Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol\/glycopyrronium: post-hoc analysis of the TRIBUTE Study","volume":"197","author":"Scuri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rmed.2017.07.060","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial","volume":"131","author":"Crim","year":"2017","journal-title":"Respir Med"},{"key":"2024102100362530000_52.6.1801219.79","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201409-413OC"},{"key":"2024102100362530000_52.6.1801219.80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61250-2"},{"key":"2024102100362530000_52.6.1801219.81","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00193908"},{"key":"2024102100362530000_52.6.1801219.82","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207021"},{"key":"2024102100362530000_52.6.1801219.83","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","article-title":"Eosinophils in COPD: just another biomarker?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.84","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","article-title":"Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.85","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00120-2018"},{"key":"2024102100362530000_52.6.1801219.86","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/DDDT.S63100","article-title":"Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia","volume":"8","author":"Cheng","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"2024102100362530000_52.6.1801219.87","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200611-1630OC"},{"key":"2024102100362530000_52.6.1801219.88","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028711"},{"key":"2024102100362530000_52.6.1801219.89","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00077010"},{"key":"2024102100362530000_52.6.1801219.90","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00077509"},{"key":"2024102100362530000_52.6.1801219.91","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201012-2070OC"},{"key":"2024102100362530000_52.6.1801219.92","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-203175"},{"key":"2024102100362530000_52.6.1801219.93","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181cafcd3"},{"key":"2024102100362530000_52.6.1801219.94","unstructured":"World Health Organization. Global tuberculosis report . Geneva, Switzerland, 2017."},{"key":"2024102100362530000_52.6.1801219.95","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201007-1099OC"},{"key":"2024102100362530000_52.6.1801219.96","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201772"},{"key":"2024102100362530000_52.6.1801219.97","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00037-2017"},{"key":"2024102100362530000_52.6.1801219.98","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/08958378.2017.1346006","article-title":"Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis","volume":"29","author":"Yang","year":"2017","journal-title":"Inhal Toxicol"},{"key":"2024102100362530000_52.6.1801219.99","doi-asserted-by":"crossref","unstructured":"Yang IA , Clarke MS , Sim EHA , et\u00a0al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane database Syst Rev 2012: CD002991.","DOI":"10.1002\/14651858.CD002991.pub3"},{"key":"2024102100362530000_52.6.1801219.100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pupt.2017.06.002","article-title":"Withdrawal of inhaled corticosteroids in COPD: a meta-analysis","volume":"45","author":"Calzetta","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102100362530000_52.6.1801219.101","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(99)90001-X"},{"key":"2024102100362530000_52.6.1801219.102","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/ajrccm.164.3.2002052","article-title":"Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction","volume":"164","author":"O'Brien","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.103","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-512OC"},{"key":"2024102100362530000_52.6.1801219.104","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.034280"},{"key":"2024102100362530000_52.6.1801219.105","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-8-93"},{"key":"2024102100362530000_52.6.1801219.106","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-107"},{"key":"2024102100362530000_52.6.1801219.107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407154"},{"key":"2024102100362530000_52.6.1801219.108","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01644-2015"},{"key":"2024102100362530000_52.6.1801219.109","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/COPD.S125616","article-title":"\u201cReal-life\u201d inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD","volume":"12","author":"Vogelmeier","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102100362530000_52.6.1801219.110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1378\/chest.14-3091","article-title":"Relapse in FEV1 decline after steroid withdrawal in COPD","volume":"148","author":"Kunz","year":"2015","journal-title":"Chest"},{"key":"2024102100362530000_52.6.1801219.111","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00839-2016"},{"key":"2024102100362530000_52.6.1801219.112","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00126814"},{"key":"2024102100362530000_52.6.1801219.113","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.114","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1164\/rccm.201805-0979ED","article-title":"To withdraw or not to withdraw inhaled corticosteroids from triple therapy in COPD","volume":"198","author":"Tashkin","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199211123272003","article-title":"A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group","volume":"327","author":"Kerstjens","year":"1992","journal-title":"N Engl J Med"},{"key":"2024102100362530000_52.6.1801219.116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1411863"},{"key":"2024102100362530000_52.6.1801219.117","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201607-1421OC","article-title":"Effect of fluticasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction","volume":"195","author":"Martinez","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.118","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-71"},{"key":"2024102100362530000_52.6.1801219.119","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201409-1654PP"},{"key":"2024102100362530000_52.6.1801219.120","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.06.019"},{"key":"2024102100362530000_52.6.1801219.121","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000368371","article-title":"Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease","volume":"89","author":"Herth","year":"2015","journal-title":"Respiration"},{"key":"2024102100362530000_52.6.1801219.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.12.001"},{"key":"2024102100362530000_52.6.1801219.123","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.160028"},{"key":"2024102100362530000_52.6.1801219.124","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2012.00092"},{"key":"2024102100362530000_52.6.1801219.125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432601"},{"key":"2024102100362530000_52.6.1801219.126","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201502-0235LE"},{"key":"2024102100362530000_52.6.1801219.127","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","article-title":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial","volume":"195","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.128","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.129","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201612-2525LE","article-title":"Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease","volume":"196","author":"Calverley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.131","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(17)30207-2","article-title":"Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort","volume":"5","author":"Han","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.132","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162414"},{"key":"2024102100362530000_52.6.1801219.133","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102100362530000_52.6.1801219.134","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024102100362530000_52.6.1801219.135","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00427-2018"},{"key":"2024102100362530000_52.6.1801219.136","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201701-0009LE","article-title":"Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts","volume":"195","author":"Oshagbemi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100362530000_52.6.1801219.137","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024102100362530000_52.6.1801219.138","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201509-1869OC"},{"key":"2024102100362530000_52.6.1801219.139","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01219-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:59:47Z","timestamp":1740362387000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01219-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":139,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1183\/13993003.01219-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01219-2018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733961540.793564087","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]}}}